JP Morgan Concerned Tesla Stock Will Crash by 60 Percent in Face of Ongoing Business Failures
Tesla’s first quarter results this year left plenty to be desired. The embattled EV maker’s sales fell short of Wall Street’s expectations,
Read MoreTesla Drops 4% as EV Demand Fears, SpaceX IPO Uncertainty, April 22 Earnings Loom Large
2024 Getty Images / Getty Images News via Getty Images
Quick Read
-
Tesla (TSLA) shares slid below $339 after the company reported Q1 2026 deliveries of 358,023 units, missing consensus by 7,000 units, while facing a P/E ratio of 334x and analyst price targets averaging $416.15.
Cramer Flags New Trade: Sell Some Tesla, Wait for SpaceX IPO?
CNBC host Jim Cramer is floating a provocative idea: Tesla Inc. investors could trim TSLA exposure now to save dry powder for the SpaceX IPO.
In a social media post reacting to JPMorgan’s fresh downgrade of Tesla to Sell, with a call for the stock to plunge roughly 60%,
» Read more about: Cramer Flags New Trade: Sell Some Tesla, Wait for SpaceX IPO? »
Read MoreGoogle just sucker-punched these highflying tech stocks — don’t let the relief rally fool you
One algorithm. Six times less memory. Zero accuracy loss. And the entire investment thesis for the AI hardware boom just got compressed along with it.
Memory-chip stocks were supposed to be the safe way to play AI.
Market Crash: The Healthcare Stocks I'd Buy Without Hesitation
With the Nasdaq Composite recently hitting correction territory, many investors fear that we will enter a full-blown bear market relatively soon. These worries are somewhat justified. While some experts warn that the odds of a recession are rising, we are still dealing with trade wars, serious geopolitical tensions, and oil prices that have risen significantly in recent weeks.
» Read more about: Market Crash: The Healthcare Stocks I'd Buy Without Hesitation »
Read MoreThe Burst
1 Organ Transplant Disruptor to Buy on the Dip
TransMedics (NASDAQ:TMDX) is an innovative biotechnology company that may well have the potential to disrupt the $11 billion organ transplant industry.
The company’s unique organ care system technology protects and monitors donor organs before they are transplanted into patients, resulting in improved organ health and outcomes. TransMedics also provides logistical services,
» Read more about: 1 Organ Transplant Disruptor to Buy on the Dip »
Read MoreThe Ivy
The Danger Is Still High, Here’s Why
After a face-ripping rally Wednesday, markets took a breather yesterday. Futures were pointing lower, which, frankly, wasn’t all that surprising given how sharply things ripped higher.
But while some have pointed to a bottom, the reality is the danger is still high. Look no further than how the rally failed at the downtrending resistance line.
» Read more about: The Danger Is Still High, Here’s Why »
Read MoreThe Spotlight
Spotlight: 1 High-paying Dividend Stock Is Way Undervalued
Wall Street analysts seem pretty gung-ho about Realty Income, pegging an average price target at $68 per share, a significant pop from where the stock sits now. That’s in addition to a dividend yield north of 6%.
Is Wall Street right or is the recent selloff indicative of what’s to come for Realty Income?
» Read more about: Spotlight: 1 High-paying Dividend Stock Is Way Undervalued »